Cellular senescence in HIV is emerging as a critical factor in the long-term health of people living with the virus. Even though modern antiretroviral therapy (ART) effectively suppresses viral replication, many patients continue to suffer from chronic inflammation. This persistent state often leads to age-related comorbidities earlier than in the general population. A recent study published in The Journal of Infectious Diseases explored how various biomarkers change across different stages of infection.

Persistent Cellular Senescence in HIV Despite Treatment

Researchers analyzed blood samples from individuals at primary, chronic, and advanced stages of HIV infection. They measured classical markers such as SA-βGal, p16INK4a, and γH2AX. Notably, the study found that individuals in chronic and advanced stages exhibited elevated senescence markers even after one year on ART. This indicates that while the medication controls the virus, it does not fully reset the cellular "aging" clock in patients who start treatment late. However, those who began ART during the primary stage of infection did not show the same level of persistent senescence.

The study also highlighted significant correlations between these biomarkers and immune health. Specifically, senescence markers in T-cells and plasma secretory factors (SASP) correlated positively with T-cell activation and HIV p24 expression. Conversely, they showed a negative correlation with CD4 counts and the CD4/CD8 ratio. Consequently, cellular senescence in HIV appears to be a major driver of immunosenescence and overall immune exhaustion.

The Clinical Promise of Senolytic Strategies

Because the current treatment paradigm fails to eliminate senescent cells, new therapeutic approaches are necessary. Senolytic and senomorphic strategies represent a promising frontier for research. These drugs aim to either selectively kill senescent cells or suppress their harmful secretory phenotypes. By targeting the root cause of "inflammaging," doctors might eventually reduce the burden of cardiovascular disease, neurocognitive decline, and other complications in people with HIV.

Frequently Asked Questions

Can early ART prevent cellular senescence in HIV?

Yes, research indicates that initiating antiretroviral therapy during the primary stage of HIV infection can prevent the persistent elevation of cellular senescence biomarkers seen in later stages.

What are SASP factors in HIV?

SASP stands for Senescence-Associated Secretory Phenotype. These are pro-inflammatory factors like IL-6 and IL-10 that senescent cells release, contributing to chronic inflammation and tissue damage.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Ayala-Suárez R et al. Changes in Cellular Senescence Biomarkers Across Individuals at Different Stages of HIV Infection Before and After a Year on Antiretroviral Therapy. J Infect Dis. 2026 Mar 09. doi: undefined. PMID: 41797680.

Rodriguez-Agustin A et al. HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells. Front Immunol. 2025 Apr 24. doi: 10.3389/fimmu.2025.1568762.

Mabonga L and Kappo AP. The Impact of HIV- and ART-Induced Mitochondrial Dysfunction in Cellular Senescence and Aging. Cells. 2021 Jan 16;10(1):174. doi: 10.3390/cells10010174.